Smoking, TobaccoNCT05789420
Nicotine Pharmacokinetics of THS Single Use of a Regular or a Menthol Stick Compared to CIG
A study testing P1R stick, P1M stick and CIG in people with Smoking, Tobacco, run by Philip Morris Products S.A. at 1 site in United Kingdom.
Trial summary
The purpose of this study was to describe the nicotine pharmacokinetic (PK) profile during and after single use of THS (Induction heating technology, with either a regular or menthol stick) compared to singular CIG smoking in healthy adult subjects. Read more about this study
- Who is it for?
- Ages 21 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Smoking, Tobacco
- What is being tested?
- P1R stick, P1M stick and CIG
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 31 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 16 Feb 2023to 5 May 2023
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Subject has signed the ICF and is able to understand the information provided in the ICF.
- Subject has been a smoker for ≥3 years prior to the screening visit (smoking cessation attempts during this period, if any, did not last > 6 months in total).
- Subject has continuously smoked on average ≥10 commercially available regular CIG/day over the last 4 weeks. Smoking status will be verified based on a urinary cotinine test (cotinine ≥200 ng/mL).
- Subject is healthy as judged by the Investigator based on available assessments from the screening period (e.g., safety laboratory, spirometry, vital signs, physical examination, ECG, and medical history).
- Subject does not plan to quit smoking within the next three months.
Who cannot join
- As per the Investigator's judgment, the subject cannot participate in the study for any reason other than medical (e.g., psychological, social reason).
- Subject is legally incompetent, or physically or mentally incapable of giving consent (e.g., in emergency situations, under guardianship, prisoners).
- Subject has a clinically relevant disease which requires medication (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, oncological, urological, immunological, pulmonary, and cardiovascular disease) or any other medical condition (including safety laboratory), which as per the judgment of the Investigator would jeopardize the safety of the subject.
- Subject experienced within 30 days prior to screening/admission a body temperature >37.5°C or an acute illness (e.g., upper respiratory-tract infection, viral infection, etc.) or the subject has a confirmed or suspected active COVID-19 infection (based on the signs and symptoms observed at the time of assessment)
- As per the Investigator's judgment, the subject has medical conditions which do or will require a medical intervention (e.g., start of treatment, surgery, hospitalization) during the study participation, which may interfere with the study participation and/or study results.
- Subject has relevant history of, or current asthma condition or COPD condition, and/or clinically significant findings.
Show all 17Show fewer
- Subject has donated blood or received whole blood or blood products within 3 months.
- BMI < 18.5 kg/m2 or ≥ 32.0 kg/m2.
- Positive serology test for HIV 1/2, HBV, or HCV.
- Subject has a positive alcohol breath test and/or has a history of alcohol disorder that could interfere with their participation in the study.
- The subject has a positive urine drug test.
- Subject or one of their family members is a current or former employee of the tobacco or e-cigarette industry.
- Subject or one of their family members is an employee of the investigational site or of any other parties involved in the study.
- Subject has participated in another clinical study within 3 months.
- Subject has been previously screened or enrolled in this study.
- Subject is pregnant (does not have negative pregnancy tests at Screening and at Baseline) or is breastfeeding.
- For women of childbearing potential only: subject does not agree to use an acceptable method of effective contraception.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Single-center, Randomized, Controlled, Open-label Study in Smoking Healthy Subjects to Investigate the Nicotine Pharmacokinetic Profiles Following Single Use of Tobacco Heating System (THS) With a Regular or a Menthol Stick, Compared to Smoking of a Single Combustible Cigarette (CIG)
The purpose of this study was to describe the nicotine pharmacokinetic (PK) profile during and after single use of THS (Induction heating technology, with either a regular or menthol stick) compared to singular CIG smoking in healthy adult subjects. In addition, pharmacodynamic effects (subjective effects) were evaluated to provide further insights on product acceptance and likelihood to use the THS again. Safety was assessed throughout the study.
Read the detailed description
General information about the research:
Study Title:
Nicotine Pharmacokinetics of THS Single Use of a Regular or a Menthol Stick Compared to CIG
Who carried out the research? This research was sponsored and funded by Philip Morris Products S.A.
What public involvement there was in the study? Thirty-one healthy, currently smoking, adults participated in this study.
Where and when the study took place? The study was conducted at a clinical trial facility managed by a contract research organization in Belfast, Northern Ireland, from February 16th to April 2nd 2023.
Why was the research needed? The research was needed to understand the nicotine pharmacokinetic profile of the Tobacco Heating System (THS), with induction heating technology, in healthy smokers following single use of THS, with a regular or menthol stick, compared to cigarette single-use.
What were the main questions studied? The study measured the amount and the time rate of nicotine uptake in blood plasma, and other parameters. These were the maximum nicotine plasma concentration [Cmax], the time to the maximum nicotine plasma concentration [Tmax], and further subsequent calculations describing the nicotine exposure profile.
Who participated in the study? Thirty-one healthy, male or female, adults aged between 21 and 65 years participated in this study. All participants were currently smoking. The participants did not plan to quit using tobacco and/or nicotine products within the next 3 months and had smoked continuously for at least the last 3 years prior to joining the study.
Each participant was given full and adequate oral and written information about the nature, purpose, possible risks, and benefits of the study.
All participants received information on the risks of smoking, smoking cessation advice and a briefing on the Tobacco Heating System, for example, that its use is not risk-free.
Once each participant had received all the necessary information, and if they agreed to participate, this was documented in an Informed Consent Form with the date, time, and signature of both the participant and the study doctor.
Participants were informed that they were free to withdraw from the study at any time.
What treatments or interventions did the participants take/receive? Thirty participants were randomly assigned to one of six possible cross-over sequences of product use (THS, with either regular or menthol stick, and cigarette) from Day 1 to Day 3 in a confinement setting.
Participants could not use any other tobacco or nicotine-containing product (TNP) other than their assigned product.
From Day 1 to Day 3, after at least 23 hours of abstinence from any TNP on Day 1, and at least 24 hours after former IP use on Day 2 and on Day 3 (nicotine washout), subjects smoked a CIG or used the THS either with a regular or a menthol THS stick according to their randomized product use sequence.
Blood samples were collected, at several time points after product use, from Day1 to Day 3, for determination of nicotine concentration after allocated product use.
Participants were also asked, from Day 1 to Day 3, to evaluate product liking, craving for cigarettes, and their intention to use the product again. These were assessed on a scale for each evaluation. The scales went from "strong disliking" to "strong liking" for product liking; from "no craving" to "strong craving" for cigarette craving; and "very unlikely" to "very likely" for intention to use again.
What medical problems (adverse reactions) did the participants have? Overall, there were six mild adverse reactions reported in four participants. All the adverse reactions were mild or moderate in severity. None of these were considered related to an investigational product.
There were no clinically significant findings in the physical examination, clinical laboratory, vital signs, or ECG assessments in this study.
What happened during the study? A presentation of THS (without product use) was made to the participants during the Screening visit. All participants received information on the risks of smoking, smoking cessation advice, and a briefing that the use of THS is not risk-free.
Eligible participants, fulfilling all criteria for participation, returned to the investigational site for admission and baseline measurements on Day -1.
Subjects fasted for at least 6 hours prior to the safety laboratory assessments and started abstinence of TNP.
Thirty subjects were randomized to one of 6 possible full cross-over sequences of product use (THS, with either regular or menthol THS stick, and cigarette) on Day 1 to Day 3.
On Day 1 to Day 3, after at least 23 hours of abstinence from any TNP on Day 1, and at least 24 hours after THS use on Day 2 and on Day 3 (nicotine washout), subjects smoked a cigarette or used the THS either with a regular or a menthol THS stick according to randomized product use sequence.
Blood samples were obtained according to the standard procedures of the investigational site. Subjects were requested to report their cigarette craving, THS liking, and intention to use the THS again.
After Discharge on Day 3 or after an early termination following product exposure, the subjects entered a 3-day Safety Follow-Up period during which adverse reactions reported by the subjects were collected and followed-up, concluded by telephone contact by the investigational site on the last day of the Safety Follow-Up period.
What were the results of the study? The nicotine exposure profiles and subjective effects of THS product use were assessed for THS tobacco sticks of different flavors (regular flavor; menthol flavor) and compared to those of cigarette smoking.
The results of this study confirmed that nicotine exposure, from both THS Regular tobacco sticks and THS Menthol tobacco sticks, showed a lower level of nicotine uptake when using the THS Induction device compared to cigarette single use. These results are in line with historical data described for the THS device with blade heating technology.
The subjective effects of THS (induction) use were comparable to those presented in previous studies that compared THS (blade) use to cigarette use, which found that cigarette use was more satisfying while THS demonstrated comparable craving reduction.
Furthermore, this study found no additional safety concerns were associated with THS compared to cigarette smoking.
How has this study helped patients and researchers? The participants in this study were healthy, current cigarette smokers. All participants were informed about the health risks associated with smoking and were given smoking cessation advice. Participants in this clinical study benefited from repeated and detailed general health check-ups.
This clinical study may help doctors and scientists learn about electronic nicotine delivery systems.
Details of any further research planned This study is part of an ongoing program of research supporting the scientific substantiation of the Tobacco Heating System.
Where can I learn more about this study?
More details about this study, including the study results and a copy of the study protocol, can be found on the clinicaltrials.gov website at this address:
https://clinicaltrials.gov/show/NCT05789420
- Conditions
- Smoking, Tobacco
- Being tested
- P1R stick, P1M stick, CIG
- Keywords
- Nicotine, Nicotine-containing products, Heated tobacco, Smoking, Tobacco, Tobacco Heating System, Pharmacokinetics
- Medical subject headings
- Tobacco Smoking, Smoking
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
P1R stickOther
Regular flavor tobacco stick
P1M stickOther
Mentholated flavor tobacco stick
CIGOther
Subjects' preferred brand of commercially available, regular or mentholated cigarettes
| Study group | Role | What they receive |
|---|---|---|
| Product Sequence 1 | Active comparator | After at least 23 hours of abstinence from any Tobacco or Nicotine Product (TNP) on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects smoked a single CIG or performed a single use of a THS either with a regular or a menthol THS stick, according to randomized product use sequence.
The list of possible sequences are:
P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R Receives: Other: P1R stick; Other: P1M stick; Other: CIG |
| Product Sequence 2 | Active comparator | After at least 23 hours of abstinence from any TNP on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects smoked a single CIG or performed a single use of a THS either with a regular or a menthol THS stick, according to randomized product use sequence.
The list of possible sequences are:
P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R Receives: Other: P1R stick; Other: P1M stick; Other: CIG |
| Product Sequence 3 | Active comparator | After at least 23 hours of abstinence from any TNP on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects smoked a single CIG or performed a single use of a THS either with a regular or a menthol THS stick, according to randomized product use sequence.
The list of possible sequences are:
P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R Receives: Other: P1R stick; Other: P1M stick; Other: CIG |
| Product Sequence 4 | Active comparator | After at least 23 hours of abstinence from any TNP on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects smoked a single CIG or performed a single use of a THS either with a regular or a menthol THS stick, according to randomized product use sequence.
The list of possible sequences are:
P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R Receives: Other: P1R stick; Other: P1M stick; Other: CIG |
| Product Sequence 5 | Active comparator | After at least 23 hours of abstinence from any TNP on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects smoked a single CIG or perform a single use of a THS either with a regular or a menthol THS stick, according to randomized product use sequence.
The list of possible sequences are:
P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R Receives: Other: P1R stick; Other: P1M stick; Other: CIG |
| Product Sequence 6 | Active comparator | After at least 23 hours of abstinence from any TNP on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects smoked a single CIG or perform a single use of a THS either with a regular or a menthol THS stick, according to randomized product use sequence.
The list of possible sequences are:
P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R Receives: Other: P1R stick; Other: P1M stick; Other: CIG |
What is being measured
The primary outcome is the main question the study is designed to answer.
Maximum Plasma Concentration [Cmax]
To measure Cmax from the single use of THS with either a regular or a menthol stick or of a single cigarette.
Measured: Measured from start of product use to 24 hours
Time to the Maximum Concentration [Tmax]
To measure Tmax from the single use of THS with either a regular or a menthol stick or of a single cigarette.
Measured: Measured from start of product use to 24 hours
Area Under the Curve of Nicotine Plasma Concentration-time Computed From T0 to T=24 Hours [AUC0-24h]
To measure AUC0-24h from the single use of THS with either a regular or a menthol stick or of a single cigarette.
Measured: Measured from start of product use to 24 hours
Area Under the Curve of Nicotine Plasma Concentration-time Computed From T0 to the Subject-specific Time of Maximum Nicotine Concentration [AUC0-t']
To measure the area under the curve of nicotine plasma concentration-time computed from T0 to the subject-specific time of maximum nicotine concentration [AUC0-t'], from the single use of THS with either a regular or a menthol stick or from a single cigarette. (AUC0-Tmax)
Measured: Measured from start of product use to 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Mar 2023
- Study start16 Feb 2023
- Primary completion2 Apr 2023
- Study completion5 May 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Smoking, TobaccoStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 31 participants (actual)
Sponsor and investigators
- Lead sponsor
- Philip Morris Products S.A.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Xavier Jaumont, MD, Study chair, Philip Morris Products S.A.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05789420
- Sponsor's protocol ID
- P1-PK-12
- Status last verified
- Sep 2024
- First submitted
- 16 Mar 2023
- Last updated
- 22 Nov 2024
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single-center, Randomized, Controlled, Open-label Study in Smoking Healthy Subjects to Investigate the Nicotine Pharmacokinetic Profiles Following Single Use of Tobacco Heating System (THS) With a Regular or a Menthol Stick, Compared to Smoking of a Single Combustible Cigarette (CIG)
- ClinicalTrials.gov ID
- NCT05789420
- Acronym / sponsor ID
- P1-PK-12
- Conditions
- Smoking, Tobacco
- Keywords
- Nicotine, Nicotine-containing products, Heated tobacco, Smoking, Tobacco, Tobacco Heating System, Pharmacokinetics
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 31 participants (actual)
- Lead sponsor
- Philip Morris Products S.A.Industry (pharma, biotech, devices)
- Study start
- 16 Feb 2023 (actual)
- Primary completion
- 2 Apr 2023 (actual)
- Study completion
- 5 May 2023 (actual)
- First posted
- 29 Mar 2023 (actual)
- Results
- Posted 22 Nov 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study was to describe the nicotine pharmacokinetic (PK) profile during and after single use of THS (Induction heating technology, with either a regular or menthol stick) compared to singular CIG smoking in healthy adult subjects. In addition, pharmacodynamic effects (subjective effects) were evaluated to provide further insights on product acceptance and likelihood to use the THS again. Safety was assessed throughout the study.
Detailed description
General information about the research:
Study Title:
Nicotine Pharmacokinetics of THS Single Use of a Regular or a Menthol Stick Compared to CIG
Who carried out the research? This research was sponsored and funded by Philip Morris Products S.A.
What public involvement there was in the study? Thirty-one healthy, currently smoking, adults participated in this study.
Where and when the study took place? The study was conducted at a clinical trial facility managed by a contract research organization in Belfast, Northern Ireland, from February 16th to April 2nd 2023.
Why was the research needed? The research was needed to understand the nicotine pharmacokinetic profile of the Tobacco Heating System (THS), with induction heating technology, in healthy smokers following single use of THS, with a regular or menthol stick, compared to cigarette single-use.
What were the main questions studied? The study measured the amount and the time rate of nicotine uptake in blood plasma, and other parameters. These were the maximum nicotine plasma concentration [Cmax], the time to the maximum nicotine plasma concentration [Tmax], and further subsequent calculations describing the nicotine exposure profile.
Who participated in the study? Thirty-one healthy, male or female, adults aged between 21 and 65 years participated in this study. All participants were currently smoking. The participants did not plan to quit using tobacco and/or nicotine products within the next 3 months and had smoked continuously for at least the last 3 years prior to joining the study.
Each participant was given full and adequate oral and written information about the nature, purpose, possible risks, and benefits of the study.
All participants received information on the risks of smoking, smoking cessation advice and a briefing on the Tobacco Heating System, for example, that its use is not risk-free.
Once each participant had received all the necessary information, and if they agreed to participate, this was documented in an Informed Consent Form with the date, time, and signature of both the participant and the study doctor.
Participants were informed that they were free to withdraw from the study at any time.
What treatments or interventions did the participants take/receive? Thirty participants were randomly assigned to one of six possible cross-over sequences of product use (THS, with either regular or menthol stick, and cigarette) from Day 1 to Day 3 in a confinement setting.
Participants could not use any other tobacco or nicotine-containing product (TNP) other than their assigned product.
From Day 1 to Day 3, after at least 23 hours of abstinence from any TNP on Day 1, and at least 24 hours after former IP use on Day 2 and on Day 3 (nicotine washout), subjects smoked a CIG or used the THS either with a regular or a menthol THS stick according to their randomized product use sequence.
Blood samples were collected, at several time points after product use, from Day1 to Day 3, for determination of nicotine concentration after allocated product use.
Participants were also asked, from Day 1 to Day 3, to evaluate product liking, craving for cigarettes, and their intention to use the product again. These were assessed on a scale for each evaluation. The scales went from "strong disliking" to "strong liking" for product liking; from "no craving" to "strong craving" for cigarette craving; and "very unlikely" to "very likely" for intention to use again.
What medical problems (adverse reactions) did the participants have? Overall, there were six mild adverse reactions reported in four participants. All the adverse reactions were mild or moderate in severity. None of these were considered related to an investigational product.
There were no clinically significant findings in the physical examination, clinical laboratory, vital signs, or ECG assessments in this study.
What happened during the study? A presentation of THS (without product use) was made to the participants during the Screening visit. All participants received information on the risks of smoking, smoking cessation advice, and a briefing that the use of THS is not risk-free.
Eligible participants, fulfilling all criteria for participation, returned to the investigational site for admission and baseline measurements on Day -1.
Subjects fasted for at least 6 hours prior to the safety laboratory assessments and started abstinence of TNP.
Thirty subjects were randomized to one of 6 possible full cross-over sequences of product use (THS, with either regular or menthol THS stick, and cigarette) on Day 1 to Day 3.
On Day 1 to Day 3, after at least 23 hours of abstinence from any TNP on Day 1, and at least 24 hours after THS use on Day 2 and on Day 3 (nicotine washout), subjects smoked a cigarette or used the THS either with a regular or a menthol THS stick according to randomized product use sequence.
Blood samples were obtained according to the standard procedures of the investigational site. Subjects were requested to report their cigarette craving, THS liking, and intention to use the THS again.
After Discharge on Day 3 or after an early termination following product exposure, the subjects entered a 3-day Safety Follow-Up period during which adverse reactions reported by the subjects were collected and followed-up, concluded by telephone contact by the investigational site on the last day of the Safety Follow-Up period.
What were the results of the study? The nicotine exposure profiles and subjective effects of THS product use were assessed for THS tobacco sticks of different flavors (regular flavor; menthol flavor) and compared to those of cigarette smoking.
The results of this study confirmed that nicotine exposure, from both THS Regular tobacco sticks and THS Menthol tobacco sticks, showed a lower level of nicotine uptake when using the THS Induction device compared to cigarette single use. These results are in line with historical data described for the THS device with blade heating technology.
The subjective effects of THS (induction) use were comparable to those presented in previous studies that compared THS (blade) use to cigarette use, which found that cigarette use was more satisfying while THS demonstrated comparable craving reduction.
Furthermore, this study found no additional safety concerns were associated with THS compared to cigarette smoking.
How has this study helped patients and researchers? The participants in this study were healthy, current cigarette smokers. All participants were informed about the health risks associated with smoking and were given smoking cessation advice. Participants in this clinical study benefited from repeated and detailed general health check-ups.
This clinical study may help doctors and scientists learn about electronic nicotine delivery systems.
Details of any further research planned This study is part of an ongoing program of research supporting the scientific substantiation of the Tobacco Heating System.
Where can I learn more about this study?
More details about this study, including the study results and a copy of the study protocol, can be found on the clinicaltrials.gov website at this address:
https://clinicaltrials.gov/show/NCT05789420
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Product Sequence 1 | Active comparator | Other: P1R stick, Other: P1M stick, Other: CIGAfter at least 23 hours of abstinence from any Tobacco or Nicotine Product (TNP) on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects smoked a single CIG or performed a single use of a THS either with a regular or a menthol THS stick, according to randomized product use sequence. The list of possible sequences are: P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R |
| Product Sequence 2 | Active comparator | Other: P1R stick, Other: P1M stick, Other: CIGAfter at least 23 hours of abstinence from any TNP on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects smoked a single CIG or performed a single use of a THS either with a regular or a menthol THS stick, according to randomized product use sequence. The list of possible sequences are: P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R |
| Product Sequence 3 | Active comparator | Other: P1R stick, Other: P1M stick, Other: CIGAfter at least 23 hours of abstinence from any TNP on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects smoked a single CIG or performed a single use of a THS either with a regular or a menthol THS stick, according to randomized product use sequence. The list of possible sequences are: P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R |
| Product Sequence 4 | Active comparator | Other: P1R stick, Other: P1M stick, Other: CIGAfter at least 23 hours of abstinence from any TNP on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects smoked a single CIG or performed a single use of a THS either with a regular or a menthol THS stick, according to randomized product use sequence. The list of possible sequences are: P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R |
| Product Sequence 5 | Active comparator | Other: P1R stick, Other: P1M stick, Other: CIGAfter at least 23 hours of abstinence from any TNP on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects smoked a single CIG or perform a single use of a THS either with a regular or a menthol THS stick, according to randomized product use sequence. The list of possible sequences are: P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R |
| Product Sequence 6 | Active comparator | Other: P1R stick, Other: P1M stick, Other: CIGAfter at least 23 hours of abstinence from any TNP on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects smoked a single CIG or perform a single use of a THS either with a regular or a menthol THS stick, according to randomized product use sequence. The list of possible sequences are: P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R |
Who may qualify
- Ages
- 21 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Subject has signed the ICF and is able to understand the information provided in the ICF.
- Subject has been a smoker for ≥3 years prior to the screening visit (smoking cessation attempts during this period, if any, did not last > 6 months in total).
- Subject has continuously smoked on average ≥10 commercially available regular CIG/day over the last 4 weeks. Smoking status will be verified based on a urinary cotinine test (cotinine ≥200 ng/mL).
- Subject is healthy as judged by the Investigator based on available assessments from the screening period (e.g., safety laboratory, spirometry, vital signs, physical examination, ECG, and medical history).
- Subject does not plan to quit smoking within the next three months.
Key exclusion criteria (17 listed)
- As per the Investigator's judgment, the subject cannot participate in the study for any reason other than medical (e.g., psychological, social reason).
- Subject is legally incompetent, or physically or mentally incapable of giving consent (e.g., in emergency situations, under guardianship, prisoners).
- Subject has a clinically relevant disease which requires medication (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, oncological, urological, immunological, pulmonary, and cardiovascular disease) or any other medical condition (including safety laboratory), which as per the judgment of the Investigator would jeopardize the safety of the subject.
- Subject experienced within 30 days prior to screening/admission a body temperature >37.5°C or an acute illness (e.g., upper respiratory-tract infection, viral infection, etc.) or the subject has a confirmed or suspected active COVID-19 infection (based on the signs and symptoms observed at the time of assessment)
- As per the Investigator's judgment, the subject has medical conditions which do or will require a medical intervention (e.g., start of treatment, surgery, hospitalization) during the study participation, which may interfere with the study participation and/or study results.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| P1R stickRegular flavor tobacco stick | Other | Product Sequence 1, Product Sequence 2, Product Sequence 3, Product Sequence 4, Product Sequence 5, Product Sequence 6 |
| P1M stickMentholated flavor tobacco stick | Other | Product Sequence 1, Product Sequence 2, Product Sequence 3, Product Sequence 4, Product Sequence 5, Product Sequence 6 |
| CIGSubjects' preferred brand of commercially available, regular or mentholated cigarettes | Other | Product Sequence 1, Product Sequence 2, Product Sequence 3, Product Sequence 4, Product Sequence 5, Product Sequence 6 |
Primary outcome
Maximum Plasma Concentration [Cmax]
Time frame: Measured from start of product use to 24 hours
To measure Cmax from the single use of THS with either a regular or a menthol stick or of a single cigarette.
Time to the Maximum Concentration [Tmax]
Time frame: Measured from start of product use to 24 hours
To measure Tmax from the single use of THS with either a regular or a menthol stick or of a single cigarette.
Area Under the Curve of Nicotine Plasma Concentration-time Computed From T0 to T=24 Hours [AUC0-24h]
Time frame: Measured from start of product use to 24 hours
To measure AUC0-24h from the single use of THS with either a regular or a menthol stick or of a single cigarette.
Area Under the Curve of Nicotine Plasma Concentration-time Computed From T0 to the Subject-specific Time of Maximum Nicotine Concentration [AUC0-t']
Time frame: Measured from start of product use to 24 hours
To measure the area under the curve of nicotine plasma concentration-time computed from T0 to the subject-specific time of maximum nicotine concentration [AUC0-t'], from the single use of THS with either a regular or a menthol stick or from a single cigarette. (AUC0-Tmax)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Nov 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Smoking, Tobacco
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Enrolling by invitationObservational study
Using Smartwatches to Monitor Smoking in Real-life Situations
Smoking
Not yet recruitingObservational study
PROMETHEE: A Shared Interregional Tele-Tobacco Cessation Platform Embedded Within the IMPULSION Lung Cancer Screening Program
Smoking Cessation, Lung Cancer Screening
Recruiting
Effectiveness of Volitional Help Sheets as an Adjunct to Treatment to Promote Behavior Change: A Pilot Study on Smoking
Tobacco Dependence
Not yet recruiting
Impacto 2.0: Mobile Smoking Cessation Across Texas
Cigarette Smoking, Smoking Cessation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Xavier Jaumont, MD study chair
Philip Morris Products S.A.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing P1R stick, P1M stick and CIG in people with Smoking, Tobacco, run by Philip Morris Products S.A. at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 22 Nov 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Maximum Plasma Concentration [Cmax] (time frame: Measured from start of product use to 24 hours). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Nov 2024.